BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Treatments for Solid Tumors

BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Treatments for Solid Tumors

SAN DIEGO, Jan. 10, 2022 -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into a clinical collaboration with Bristol Myers Squibb (NYSE: BMY) to investigate BioAtla's two lead CAB-ADC candidates, BA3011 and BA3021, in combination with Bristol Myers Squibb's anti-PD-1 therapy Opdivo® (nivolumab).

Under the terms of the agreement, BioAtla and Bristol Myers Squibb will collaborate on clinical trials of separate combination therapies using two of BioAtla's Conditionally Active Biologic Antibody Drug Conjugates, BA3011 and BA3021, each in combination with Opdvio. BioAtla will serve as the study sponsor and will be responsible for costs associated with the trial execution. Bristol Myers Squibb will provide Opdivo clinical drug supply for the study.

Pappas, Chiesi Venture Fund Joins Ranks of Pharma & VC Partnerships

Pappas, Chiesi Venture Fund Joins Ranks of Pharma & VC Partnerships

Art Pappas has overseen his own firm’s venture capital investments for 20 years. Now the veteran life sciences investor is adding on a new role, scoping out investment opportunities for a pharmaceutical company’s new venture fund.

Italian pharma Chiesi Group’s recently-launched Chiesi Ventures will focus on investing in companies developing treatments for rare and orphan diseases. The bulk of the money for investments will come from Chiesi, but the fund will be managed by Durham, NC-based A.M. Pappas & Associates, whose own investing unit, Pappas Ventures, has backed numerous companies that have found exits via acquisition or initial public offering.

Chiesi Launches Venture Capital Fund via Strategic Collaboration with A. M. Pappas & Associates

Chiesi Launches Venture Capital Fund via Strategic Collaboration with A. M. Pappas & Associates

Strategic Collaboration to Focus on Rare Disease Early Stage Investment Opportunities

PARMA, Italy and RESEARCH TRIANGLE PARK, North Carolina, September 2, 2014 /PRNewswire/ -- The Chiesi Group announced today the launch of its venture capital fund, Chiesi Ventures, via a strategic collaboration with A. M. Pappas & Associates.

Chiesi Ventures will complement the strategic interest of the Chiesi Group in the area of rare diseases by investing in early stage opportunities and expanding the Chiesi network in the US among universities, venture capital investors, rare disease patient organizations and entrepreneurial companies developing treatments for rare diseases.

MUSC Foundation for Research Development welcomes Art Pappas to board

Pappas to share venture capital expertise in pharmaceutical and life sciences industries

CHARLESTON, SC - April 23, 2014 - The Medical University of South Carolina Foundation for Research Development (FRD) has announced that venture capitalist Art Pappas has joined the organization’s Board of Directors, effective immediately.

Pappas Ventures Promotes Scott Weiner to Partner

RESEARCH TRIANGLE PARK, N.C., Jan. 8, 2014 /PRNewswire/ -- Pappas Ventures, a life science venture capital firm, announced today that Scott Weiner, who joined the firm in 2006, has been promoted to Partner.

"We are pleased to recognize Scott's many contributions to the development and success of our firm," said Art Pappas, Managing Partner at Pappas Ventures. "His knowledge of the life sciences industry and broad transaction experience is valued immensely both by my Pappas colleagues and by our many portfolio companies."

Among the many Pappas Ventures portfolio companies with which Mr. Weiner has been involved, he played a key role in the firm's successful investments in TESARO, Achillion Pharmaceuticals and Athersys. He currently serves as a director for Gentis and Milestone Pharmaceuticals, and as an observer for IlluminOss Medical, Liquidia Technologies and Thrasos Therapeutics.

Pappas Ventures Names Franz B. Humer as Venture Partner and Senior Advisor

RESEARCH TRIANGLE PARK, N.C., Dec. 10, 2013 /PRNewswire/ -- Pappas Ventures, a life science venture capital firm, announced today the appointment of Franz B. Humer as a Venture Partner and Senior Advisor with the firm. Dr. Humer is currently the Chairman of Roche Holding Ltd, a position he will retire from in March 2014.

Dr. Humer brings a wealth of leadership experience from the pharmaceutical and life science industry, including a transformative 15-year tenure as Chairman and/or Chief Executive Officer of Roche. He previously served as Chief Operating Officer and Head of Pharmaceuticals for F. Hoffmann-La Roche Ltd.

Art Pappas Elected to NVCA Board of Directors

RESEARCH TRIANGLE PARK, N.C., May 15, 2013 — The National Venture Capital Association (NVCA) today announced the election of Arthur M. Pappas, managing partner of Pappas Ventures, to its board of directors. He will serve a four-year term. The appointment was made official at the association’s annual meeting – VentureScape 2013 – in San Francisco.

Mr. Pappas has over 30 years of operating experience as a pharmaceutical and biotechnology industry executive and venture capital investor in life science companies. He founded Pappas Ventures in 1994, and works with a team that has invested in numerous life science companies that have created novel innovative products addressing unmet medical needs. Prior to forming Pappas Ventures, he held senior level leadership positions at several multinational pharmaceutical companies, for which he led operations and was responsible for the development, licensing and launch of a number of global products.

The NVCA serves as the venture capital community’s trade association, representing more than 400 members by advocating for policies that encourage innovation and reward long term investment.

Ultragenyx Press Release: Ultragenyx Appoints Eric Yuen, MD as Chief Medical Officer and Senior Vice President

NOVATO, CA –May 1, 2013 - Ultragenyx Pharmaceutical Inc., a biotechnology company focused on the development of treatments for rare and ultra-rare genetic disorders, today announced it has appointed Eric Yuen, MD as its Chief Medical Officer and Senior Vice President.  In this new role, Dr. Yuen will provide leadership and direction to Clinical Operations, Clinical Affairs, Clinical Sciences, Data Management/Biometrics, and Drug Safety.  He will report to Dr. Emil Kakkis, CEO, and will serve on the Senior Management Team.

Dr. Yuen brings over 19 years of clinical development experience in academia and industry.   In 2004, Dr. Yuen joined Johnson & Johnson as Senior Director and Neurology Franchise Medical Leader.   During his tenure at J&J, he also held several executive positions including Vice President, Therapeutic Area Head, CNS in 2006 and Vice President, Scientific Licensing from 2008 to 2009.  Dr. Yuen joins Ultragenyx from Janssen Alzheimer Immunotherapy R&D, LLC, a J&J affiliate, where he was the Head of Clinical Development since 2009.  Prior to J&J, Dr. Yuen also served as Director of Clinical Research, Department of Clinical Neuroscience at the Merck Research Laboratories. 

“As a board-certified neurologist, Dr. Yuen’s addition to the management team at Ultragenyx will provide critical support in advancing our clinical programs,” said Dr. Kakkis.  “His clinical vision and proven leadership, as well as his extensive medical and research experience, will strengthen our clinical development efforts and support the progress of our product pipeline.”

Dr. Yuen commented, “I am excited about being a part of a dedicated team focused on developing novel treatments for rare disease patients who have no approved treatments and applying my experiences in clinical development and neuromuscular diseases to help solve the devastating medical problems of these metabolic genetic diseases.” 

Dr. Yuen received his undergraduate training at Stanford University and his M.D. from the University of Chicago, Pritzker School of Medicine.  He completed his residency in Neurology and post-doctoral fellowships at the University of California, San Francisco.  Before joining industry in 2000, Dr. Yuen was a faculty member at the University of Washington, serving as a clinical investigator, studying treatments for ALS, neuropathy and multiple sclerosis. 

About Ultragenyx

Ultragenyx is a privately held, development-stage biotechnology company committed to bringing to market life-transforming therapeutics for patients with rare and ultra-rare metabolic genetic diseases.  The company focuses on diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no effective treatments. 

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics.  Ultragenyx’ strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency. 

For more information on Ultragenyx, please visit the company’s website at